Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 + Pembrolizumab vs Chemotherapy + Pembrolizumab in 1L PD-L1 Negative Non-Squamous NSCLC
NCT06711900Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Kelun-Biotech. Started Oct 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06711900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711900.